Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment
Authors:
Top Cited Papers
- 8 October 2024
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (42) , 28502-28530
Abstract
Proteolysis targeting chimeras (PROTACs) represent a transformative class of therapeutic agents that leverage the intrinsic protein degradation machinery to modulate the hemostasis of key disease-associated proteins selectively. Although several PROTACs have been approved for clinical application, suboptimal therapeutic efficacy and potential adverse side effects remain challenging. Benefiting from the enhanced targeted delivery, reduced systemic toxicity, and improved bioavailability, nanomedicines can be tailored with precision to integrate with PROTACs which hold significant potential to facilitate PROTAC nanomedicines (nano-PROTACs) for clinical translation with enhanced efficacy and reduced side effects. In this review, we provide an overview of the recent progress in the convergence of nanotechnology with PROTAC design, leveraging the inherent properties of nanomaterials, such as lipids, polymers, inorganic nanoparticles, nanohydrogels, proteins, and nucleic acids, for precise PROTAC delivery. Additionally, we discuss the various categories of PROTAC targets and provide insights into their clinical translational potential, alongside the challenges that need to be addressed.Keywords
Funding Information
- Ministry of Education - Singapore (MOET2EP30220-0010, MOE-T2EP30221-0004)
- National Research Foundation Singapore (NRF-NRFI07-2021-0005)
- National Natural Science Foundation of China (52403376)
This publication has 259 references indexed in Scilit:
- A PROTAC Augmenter for Photo‐Driven Pyroptosis in Breast CancerAdvanced Materials, 2024
- PROTAC Prodrug‐Integrated Nanosensitizer for Potentiating Radiation Therapy of CancerAdvanced Materials, 2024
- Synergizing CXCL9 with BRD4‐PROTAC Using Nanochaperone Boosts Robust T Cell‐Dependent Antitumor Immune Responses for Cancer ImmunotherapyAdvanced Functional Materials, 2024
- Exploiting Cancer Vulnerabilities by Blocking of the DHODH and GPX4 Pathways: A Multifunctional Bodipy/PROTAC Nanoplatform for the Efficient Synergistic Ferroptosis TherapyAdvanced Healthcare Materials, 2023
- A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced ImmunotherapyAdvanced Materials, 2023
- Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐ImmunotherapyAdvanced Materials, 2022
- Homotypic Targeting Delivery of siRNA with Artificial Cancer CellsAdvanced Healthcare Materials, 2020
- Genomic organization, promoter analysis, and chromosomal mapping of the mouse gene encoding Cdk9Journal of Cellular Biochemistry, 2000
- Cloning of murine CDK9/PITALRE and its tissue-specific expression in developmentJournal of Cellular Physiology, 1998
- Tissue ferritin concentration in carcinoma of the breastCancer, 1982